Documenting the complete resolution rates of venous thromboemboli (VTE) with the factor Xa inhibitor fondaparinux sodium (FS) in patients with cancer.

9130 Background: Cancer patients have a significant risk of VTE. Recurrent VTE rates of 9-17% occur (Lee NEJM 2003) despite the use of therapeutic anticoagulation (AC). Low molecular weight heparins (LMWH) afford several advantages over warfarin. Nevertheless, even with LMWHs more than 20% of patients have VTE propagation. Completeresolution and partial resolution of DVTs occur in up to 38% and 54%, respectively, after 6 months of AC (Prandoni Ann Intern Med 2002, Piovella Haematologica 2002), and thrombi remaindetectable in half of non-cancer patients after a year (Kearon Circulation 2003). Recently, Factor Xa inhibitors have become available and require further study to determine if they offer therapeutic improvements in this patient population. As part of the CAT (Cancer and Thrombosis) trial, we prospectively evaluated complete resolution rates with the Factor Xa inhibitor fondaparinux sodium (FS). Methods: Inclusion criteria included an acute VTE (DVT and/or PE) in patients with cancer and creatinine...